TICKERNERD
Menu
TEMTEMHealthcare · Health Information Services

TEM Stock Forecast: Tempus AI, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$76
−2.79% on the day

The 20 Wall Street analysts covering Tempus AI, Inc. hold a median 12-month price target of $87 — +15.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 4 Nov 2026 — in the lower half.

Market cap
$14.2B
Ticker Nerd rank
40/ 100
Median analyst target
$87
Analysts covering
20
Revenue$382.5M+21.6% y/y
Operating income−$75.9M
Net income$5.6M
Free cash flow−$18.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
−1.3%
YTD
+28.1%
1Y
−10.5%
From 52W high
−11.1%
From 52W low
+82.0%
$42
$85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TEM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tempus AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
91
Quality
59
Value
54
Momentum
49
Growth
46
Accruals
39
Issuance
25
Volatility
17
Size
13

Revisions (91): Analysts have, on balance, been raising their forecasts.

Volatility (17): The share price moves around a lot.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

TEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$50$60$70$80$90$100Jan 26Apr 26Jul 26Oct 26TEMHigh $100Median $87Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
10 Buy10 Hold0 Sell
Low $50Median $87High $100

The green dot is the last close — the median target sits +15.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 12 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Nov 2026BairdMaintainsOutperform$85 → $92
3 Nov 2026BTIGMaintainsBuy$80 → $100
3 Nov 2026Cantor FitzgeraldMaintainsOverweight$80 → $92
3 Nov 2026Freedom Capital MarketsMaintainsHold$73 → $89
3 Nov 2026HC Wainwright & Co.MaintainsBuy$68 → $85
3 Nov 2026JefferiesUpgradeHold$35 → $70
2 Nov 2026NeedhamMaintainsBuy$75 → $89
26 Oct 2026BTIGReiteratesBuy$80
26 Oct 2026HC Wainwright & Co.MaintainsBuy$66 → $68
23 Oct 2026NeedhamReiteratesBuy$75
14 Oct 2026JP MorganMaintainsNeutral$45 → $70
14 Oct 2026JP MorganMaintainsNeutral—
12 Oct 2026Canaccord GenuityMaintainsBuy$80 → $95
12 Oct 2026Canaccord GenuityMaintainsBuy—
1 Oct 2026GuggenheimMaintainsBuy$65 → $92
1 Oct 2026GuggenheimMaintainsBuy—
21 Sept 2026Goldman SachsInitiatesNeutral—
21 Sept 2026Goldman SachsInitiatesNeutral$75
11 Sept 2026HC Wainwright & Co.MaintainsBuy$56 → $66
11 Sept 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TEM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

TEM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Tempus AI, Inc. returned −10.5% against +14.8% for the S&P 500, dividends included.

TEM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26TEMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Tempus AI, Inc. (TEM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.3×

Cheaper than 19% of US stocks

Price / sales
9.1×

Cheaper than 14% of US stocks

Price / book
27.3×

Cheaper than 3% of US stocks

EV / EBITDA
−74.9×

Cheaper than 96% of US stocks

Growth & margins
Revenue growth (YoY)
23.1%

Higher than 72% of US stocks

Earnings growth (YoY)
21.6%

Higher than 61% of US stocks

Gross margin
64.4%

Higher than 78% of US stocks

Operating margin
−13.8%

Higher than 23% of US stocks

Net margin
−12.5%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−37.5%

Higher than 25% of US stocks

Return on assets
−7.4%

Higher than 29% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tempus AI, Inc. (TEM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tempus AI, Inc. has a market value of $14.2B and an enterprise value of $15.0B.

  • Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 23.1% year on year.

  • Net income over the same four quarters: −$254.4M, a −17.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$273.0M, after $9.8M of capital spending.

  • Shares outstanding: 180.2M.

  • Trailing P/E: 39.3×; forward P/E: −13220.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tempus AI, Inc. employs 3,800 people — $377K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

TEM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
TEMTempus AI, Inc.$14.2B40
BTSGBrightSpring Health Services, Inc.$13.5B93
HNGEHinge Health, Inc.$9.4B86
HQYHealthEquity, Inc.$9.3B95
DOCSDoximity, Inc.$6.4B73
WAYWaystar Holding Corp.$5.7B40
HTFLHeartFlow, Inc.$4.9B46

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tempus AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TEM news & analysis

Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)

Seeking Alpha · 4 Nov 2026positive

Tempus AI reported Q3 revenue growth of 23% year over year, following four quarters of deceleration. Diagnostics volumes rose, including a 300% increase in MRD tests, while Data & Applications revenue growth accelerated to 33%; the excerpt also cites partnerships with Bristol Myers Squibb, Moderna, and Merck.

Why it matters — The results and partnerships highlight changes in TEM's growth trends and activity across its diagnostics and data businesses.

Tempus AI Surges on Earnings Beat, But Can the Rally Last?

MarketBeat · 3 Nov 2026neutral

MarketBeat describes Tempus AI as a volatile AI-related stock that has traded in a wide range and tested upper limits several times since its IPO. The excerpt attributes its volatility to factors including the path to profitability, cash burn, and the scale of the opportunity.

Why it matters — TEM watchers may note that profitability, cash burn, and the opportunity are cited as factors shaping the stock’s volatility.

TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside

Zacks Investment Research · 3 Nov 2026positive

Tempus AI raised its 2026 revenue outlook, citing oncology demand, expanding data partnerships and reimbursement-driven pricing gains that it expects to support growth prospects for 2027.

Why it matters — The update highlights factors affecting TEM’s revenue outlook and anticipated pricing dynamics.

Baron SMID Cap ETF Q3 2026 Contributors And Detractors

Seeking Alpha · 3 Nov 2026positive

Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming the Russell 2500 Growth Index, which returned -10.35%. Tempus AI was listed among the ETF’s top contributors.

Why it matters — TEM watchers may note that Tempus AI contributed positively to the ETF’s quarterly performance.

FAQ

Frequently asked questions about TEM stock

What is the TEM stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Tempus AI, Inc. have a median 12-month price target of $87, with estimates ranging from $50 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TEM stock a buy right now?

Of the 20 analysts covering Tempus AI, Inc., 10 rate it a Buy, 10 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tempus AI, Inc. 40 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TEM?

As at 4 Nov 2026, Tempus AI, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (91 of 100).

Will TEM stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +15.0% from the last close, and Ticker Nerd's factor model ranks Tempus AI, Inc. 40 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TEM stock forecast for 2030?

No analyst covering Tempus AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $100 over the next 12 months.

How has TEM stock performed over the past year?

Tempus AI, Inc. returned -10.5% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tempus AI, Inc. do?

Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development.

What is the latest news on TEM?

The most recent item we track (Seeking Alpha, 4 Nov 2026): "Tempus AI: An Inflection Point Has Arrived (Earnings Analysis)". Tempus AI reported Q3 revenue growth of 23% year over year, following four quarters of deceleration. Diagnostics volumes rose, including a 300% increase in MRD tests, while Data & Applications revenue growth accelerated to 33%; the excerpt also cites partnerships with Bristol Myers Squibb, Moderna, and Merck.

Company

About Tempus AI, Inc.

Tempus AI Inc Class A Common Stock is the equity of Tempus AI, a healthcare technology company focused on applying artificial intelligence and machine learning to precision medicine. The company develops AI-enabled solutions that help physicians use clinical and molecular data to support more personalized care, while also providing tools and services that assist life-sciences customers with research, diagnostics, and therapeutic development. Its current business is organized around genomics, data, and artificial intelligence applications, with products spanning next-generation sequencing, molecular profiling, clinical decision support, and software-based diagnostic tools. Tempus AI serves healthcare providers, researchers, and pharmaceutical and biotechnology companies across oncology and other clinical areas, including cardiology, neuropsychiatry, infectious disease, and radiology. The stock represents ownership in a company positioned at the intersection of healthcare, data analytics, and diagnostic innovation.

CEO Mr. Eric P. Lefkofsky J.D. · 3,800 employees · United States · https://www.tempus.com